Developer docs
API playgroundTry for free, no card

Search company profiles

KIYATEC

Full company profile

uuid00027vh

Namestring
KIYATEC
Legal namestring
Kiyatec, Inc.
Websiteurl
kiyatec.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Kiyatec is a privately held functional precision oncology company headquartered in Greenville, South Carolina, that operates a CLIA-certified laboratory and commercializes a proprietary ex vivo 3D cell culture platform. The company's core technology creates up to 1,000 patient-specific microtumors (spheroids) from a patient's live cancer cells and measures their direct response to a panel of chemotherapy agents, generating a functional prediction of therapeutic response in 7-10 days before treatment begins. Its commercial clinical offering is 3D Predict Glioma (CPT Code 0248U), which predicts response to 12 chemotherapy agents in newly diagnosed and recurrent high-grade glioma patients, with published peer-reviewed evidence of 85% prediction accuracy and 5.8-month PFS and 7.6-month OS improvements in test-predicted responders versus nonresponders.

The company's revenue model combines insurance- and Medicare-billed clinical testing for healthcare providers with preclinical contract research services (KIYA-Predict) sold to biopharmaceutical customers such as AstraZeneca and XenoSTART. KIYATEC distributes through direct physician ordering, ships specimen collection kits via UPS Healthcare to its Greenville lab, and returns results through a HIPAA-compliant portal; the test is currently available across most US states except California, New York, and Rhode Island. The company is expanding the platform into additional tumor types — ovarian cancer (2025 launch), NSCLC chemotherapy (2026), and breast cancer (2027) — and in November 2025 received a strategic investment from South Korean firm MBD to integrate automation technology and accelerate US commercial expansion.

KIYATEC is venture-backed, having raised approximately $30-31M cumulatively including an $18M Series C led by Bruker in December 2022, with additional investors including LabCorp, Seae Ventures, VentureSouth, the Brain Tumor Investment Fund, and the Sontag Innovation Fund. The leadership team includes CEO Eric Perreault (formerly of LumiraDx, Lumos Diagnostics, Astute Medical), CSO Tessa DesRochers, PhD, and strategic advisor Mark Capone, former CEO of Myriad Genetics, with co-founder Matt Gevaert, PhD, now serving on the Board.

Short descriptiontext

Kiyatec is a privately held functional precision oncology company that uses patient-derived 3D microtumor assays to predict cancer therapy response, serving neuro-oncologists with its CLIA-certified 3D Predict Glioma clinical test and biopharmaceutical companies with preclinical contract research services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGreenville, United States
HQ citystring
Greenville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
functional precision oncology, 3D cell culture, cancer diagnostic testing, preclinical drug screening, patient-derived spheroids
Industry3 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAANAD
Molecular Tumor Boards & Clinical Interpretation Services
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
NAICS code2 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Functional Precision Oncology Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Clinical Testing Services
TypeOne Time License
Description

Revenue generated from clinical testing services offered to healthcare providers and patients. The 3D Predict Glioma test is commercially available in the US for high-grade glioma patients. The company bills insurance directly and offers financial assistance for uninsured or underinsured patients.

kiyatec.com
2Drug Development Services (KIYA-Predict)
TypeProfessional Services
Description

Preclinical contract testing services for biopharmaceutical companies to assess therapeutic efficacy of investigational drug candidates using 3D spheroid screening platform. Services support preclinical drug development across solid tumor types.

kiyatec.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
13D Predict Glioma test - insurance billed
ModelOtherBilling cadencePay-as-you-go
Notes

Kiyatec bills insurance directly for the 3D Predict Glioma test. Patients may receive an Explanation of Benefits (EOB) which is not a bill. If insurance denies coverage, Kiyatec works on behalf of patients to appeal. Financial assistance available for qualifying patients.

kiyatec.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
13D-Predict
Description

A proprietary ex vivo 3D cell culture technology platform that delivers patient-specific evidence of response to chemotherapy prior to treatment initiation using 3-dimensional spheroids created from patients' live cancer cells.

kiyatec.com
+2 more records
Core offering1 text field

KIYATEC operates a proprietary ex vivo 3D cell culture platform that creates up to 1,000 patient-specific microtumors from live cancer cells to predict therapeutic response to chemotherapy before treatment initiation. The company offers the 3D Predict Glioma clinical test (CLIA-certified, CPT 0248U) for newly diagnosed and recurrent high-grade glioma patients screening 12 chemotherapy agents with 7-10 day turnaround, and the KIYA-Predict preclinical service line for biopharmaceutical companies to evaluate investigational oncology drug candidates.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 85% accurate prediction of clinical response/nonresponse to temozolomide in newly diagnosed HGG patients (P=0.007)
+5 more records
Product overview1 text field

KIYATEC is a functional precision oncology company offering a unified platform centered on its proprietary 3D Predict technology. The core 3D Predict Platform uses ex vivo 3D cell culture to create patient-specific microtumors and predict therapeutic response before treatment begins. Commercial offerings include 3D Predict Glioma (CLIA-certified clinical test for high-grade glioma) and KIYA-Predict (preclinical services for biopharmaceutical drug development). The expanding pipeline includes 3D Predict tests for ovarian cancer (2025), non-small cell lung cancer (2026), and breast cancer (2027). The platform delivers results within 7-10 days and has published peer-reviewed evidence correlating predictions to actual patient outcomes.

Product and service3 records
13D Predict Glioma
CategoryClinical cancer diagnostic test
Description

A CLIA-certified clinical test for newly diagnosed and recurrent high-grade glioma patients that predicts therapeutic response to 12 chemotherapy agents including temozolomide, using patient-derived 3D spheroid cultures. Offered to neuro-oncologists, oncologists, and neurosurgeons through direct physician ordering, with results returned within 7-10 days and insurance/Medicare billed directly.

23D Predict Platform
CategoryProprietary functional precision oncology platform
Description

A proprietary ex vivo 3D cell culture platform that creates up to 1,000 patient-specific microtumors from live cancer cells to predict therapeutic response to cancer treatments before treatment initiation. Underlies Kiyatec's clinical tests and preclinical pharma services.

3KIYA-Predict
CategoryPreclinical contract research services for biopharmaceutical companies
Description

A preclinical drug development service platform that enables biopharmaceutical companies to assess therapeutic efficacy of investigational drug candidates using patient-derived 3D spheroid screening, supporting clinical candidate selection and translational oncology programs across solid tumor types.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-13
Description

South Korean firm MBD made a strategic investment to accelerate Kiyatec's US commercial expansion. Partnership involves integrating MBD's automation technology into Kiyatec's Greenville, SC laboratory to improve operational efficiency and accelerate launch of diagnostic panels for various cancers.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-27
Description

Collaboration to provide correlative ex vivo efficacy data using Kiyatec's 3D spheroid screening platform with XenoSTART's Patient Derived Xenograft (XPDX) models. Partnership helps biopharma rapidly assess efficacy, reduce drug development costs, and expedite the development process.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-23
Description

Multifaceted research agreement to assess therapeutic efficacy of undisclosed preclinical assets using Kiyatec's KIYA-Predict platform. Agreement aligns with AstraZeneca's strategy of implementing novel oncology solutions with outside partners to develop novel cancer therapeutics.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-10-10
Description

Partnership to improve tissue quality for more accurate tumor response prediction. NICO's automated Myriad tissue resection device and Automated Preservation System (APS) collects and biologically preserves tissue in the operating suite, maintaining tumor microenvironment for better predictive accuracy.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Natera is a molecular diagnostics company with a growing oncology franchise (Signatera MRD, etc.). It is a broader oncology diagnostics incumbent, addressing different clinical questions (MRD, monitoring) than KIYATEC but competing for the same oncology budget and physician relationships.

TypeBroad incumbent
Description

Caris provides molecular profiling (DNA/RNA sequencing and AI-driven biomarker analysis) across oncology and has expanded into therapy selection. It competes for the same oncology diagnostic ordering channel and serves biopharma with companion diagnostic services, overlapping with KIYATEC's clinical and pharma customers.

TypeDirect peer
Description

Champions Oncology offers patient-derived xenograft (PDX) models and translational oncology services for both preclinical drug development and clinical decision support. It is highly comparable to KIYATEC's KIYA-Predict business (preclinical efficacy testing) and overlaps with the clinical side via PDX-guided therapy selection.

TypeBroad incumbent
Description

Exact Sciences is a major molecular diagnostics company (Cologuard, Oncotype DX, etc.) with an expanding oncology portfolio. It is a broad incumbent in cancer diagnostics that competes for oncologist mindshare, though its platform is largely genomic rather than functional.

TypeBroad incumbent
Description

Foundation Medicine (a Roche subsidiary) is the established leader in comprehensive genomic profiling of solid tumors. It is a broad incumbent in oncology diagnostics, embedded in NCCN guidelines, and competes with KIYATEC for oncologist ordering behavior — though it focuses on genomic rather than functional testing.

6Tempus Labs
TypeBroad incumbent
Description

Tempus is a large, multi-modal precision medicine company offering genomic sequencing, AI-driven clinical decision support, and data services across oncology. It is a broader incumbent than KIYATEC — competing for the same oncologist wallet share via molecular profiling — and increasingly adjacent on the functional side through its broader portfolio.

7SEngine Precision Medicine
TypeDirect peer
Description

SEngine Precision Medicine applies patient-derived 3D tumor cultures and high-throughput drug screening to match cancer patients to effective therapies. It directly parallels KIYATEC's 3D Predict methodology (ex vivo 3D cultures + drug panel testing) and serves the same oncologist/patient segment in functional precision oncology.

8Notable Labs
TypeDirect peer
Description

Notable Labs is a functional precision oncology company that uses patient-derived tumor cells to test drug response ex vivo and predict therapy outcomes. It targets the same clinical use case as KIYATEC's 3D Predict — predicting individual cancer patient response before treatment — making it the closest head-to-head comparable in functional precision medicine.

9Function Oncology
TypeEmerging player
Description

Function Oncology is an earlier-stage company applying functional genomics and precision oncology approaches to identify patient-specific therapeutic vulnerabilities. It overlaps with KIYATEC's functional precision oncology thesis but is at an earlier stage and uses a different (functional genomics) underlying technology.

TypeDirect peer
Description

Certis Oncology builds patient-derived 3D tumor models and offers preclinical and translational oncology services for biopharma. It mirrors the KIYA-Predict preclinical service offering (functional/3D efficacy testing for pharma) and competes for the same biopharma customers evaluating investigational oncology assets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

KIYATEC

Functional Precision Oncology Diagnosticskiyatec.com

Kiyatec is a privately held functional precision oncology company that uses patient-derived 3D microtumor assays to predict cancer therapy response, serving neuro-oncologists with its CLIA-certified 3D Predict Glioma clinical test and biopharmaceutical companies with preclinical contract research services.

What KIYATEC does

Kiyatec is a privately held functional precision oncology company headquartered in Greenville, South Carolina, that operates a CLIA-certified laboratory and commercializes a proprietary ex vivo 3D cell culture platform. The company's core technology creates up to 1,000 patient-specific microtumors (spheroids) from a patient's live cancer cells and measures their direct response to a panel of chemotherapy agents, generating a functional prediction of therapeutic response in 7-10 days before treatment begins. Its commercial clinical offering is 3D Predict Glioma (CPT Code 0248U), which predicts response to 12 chemotherapy agents in newly diagnosed and recurrent high-grade glioma patients, with published peer-reviewed evidence of 85% prediction accuracy and 5.8-month PFS and 7.6-month OS improvements in test-predicted responders versus nonresponders.

The company's revenue model combines insurance- and Medicare-billed clinical testing for healthcare providers with preclinical contract research services (KIYA-Predict) sold to biopharmaceutical customers such as AstraZeneca and XenoSTART. KIYATEC distributes through direct physician ordering, ships specimen collection kits via UPS Healthcare to its Greenville lab, and returns results through a HIPAA-compliant portal; the test is currently available across most US states except California, New York, and Rhode Island. The company is expanding the platform into additional tumor types — ovarian cancer (2025 launch), NSCLC chemotherapy (2026), and breast cancer (2027) — and in November 2025 received a strategic investment from South Korean firm MBD to integrate automation technology and accelerate US commercial expansion.

KIYATEC is venture-backed, having raised approximately $30-31M cumulatively including an $18M Series C led by Bruker in December 2022, with additional investors including LabCorp, Seae Ventures, VentureSouth, the Brain Tumor Investment Fund, and the Sontag Innovation Fund. The leadership team includes CEO Eric Perreault (formerly of LumiraDx, Lumos Diagnostics, Astute Medical), CSO Tessa DesRochers, PhD, and strategic advisor Mark Capone, former CEO of Myriad Genetics, with co-founder Matt Gevaert, PhD, now serving on the Board.

KIYATEC firmographics

Firmographics
Name
KIYATEC
Legal name
Kiyatec, Inc.
Website
https://kiyatec.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Kiyatec is a privately held functional precision oncology company that uses patient-derived 3D microtumor assays to predict cancer therapy response, serving neuro-oncologists with its CLIA-certified 3D Predict Glioma clinical test and biopharmaceutical companies with preclinical contract research services.
Ownership category
akta.pro rank

KIYATEC industry classification

Industry
Product category
Functional Precision Oncology Diagnostics
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAANAD
Molecular Tumor Boards & Clinical Interpretation Services
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools

Keywords

  • Functional precision oncology
  • 3D cell culture
  • Cancer diagnostic testing
  • Preclinical drug screening
  • Patient-derived spheroids

Where KIYATEC is headquartered

Location

Headquarters

HQ city
Greenville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

KIYATEC business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Clinical Testing Services: Revenue generated from clinical testing services offered to healthcare providers and patients. The 3D Predict Glioma test is commercially available in the US for high-grade glioma patients. The company bills insurance directly and offers financial assistance for uninsured or underinsured patients.
  2. Drug Development Services (KIYA-Predict): Preclinical contract testing services for biopharmaceutical companies to assess therapeutic efficacy of investigational drug candidates using 3D spheroid screening platform. Services support preclinical drug development across solid tumor types.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-go3D Predict Glioma test - insurance billed

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

KIYATEC product offering

Product offering

Core offering

KIYATEC operates a proprietary ex vivo 3D cell culture platform that creates up to 1,000 patient-specific microtumors from live cancer cells to predict therapeutic response to chemotherapy before treatment initiation. The company offers the 3D Predict Glioma clinical test (CLIA-certified, CPT 0248U) for newly diagnosed and recurrent high-grade glioma patients screening 12 chemotherapy agents with 7-10 day turnaround, and the KIYA-Predict preclinical service line for biopharmaceutical companies to evaluate investigational oncology drug candidates.

Product overview

KIYATEC is a functional precision oncology company offering a unified platform centered on its proprietary 3D Predict technology. The core 3D Predict Platform uses ex vivo 3D cell culture to create patient-specific microtumors and predict therapeutic response before treatment begins. Commercial offerings include 3D Predict Glioma (CLIA-certified clinical test for high-grade glioma) and KIYA-Predict (preclinical services for biopharmaceutical drug development). The expanding pipeline includes 3D Predict tests for ovarian cancer (2025), non-small cell lung cancer (2026), and breast cancer (2027). The platform delivers results within 7-10 days and has published peer-reviewed evidence correlating predictions to actual patient outcomes.

Differentiator

Problem solved

Functional benefit

Brands

  • 3D-Predict: A proprietary ex vivo 3D cell culture technology platform that delivers patient-specific evidence of response to chemotherapy prior to treatment initiation using 3-dimensional spheroids created from patients' live cancer cells.
  • KIYA-Predict
  • 3D Predict Glioma

Products and services

  • 3D Predict Glioma A CLIA-certified clinical test for newly diagnosed and recurrent high-grade glioma patients that predicts therapeutic response to 12 chemotherapy agents including temozolomide, using patient-derived 3D spheroid cultures. Offered to neuro-oncologists, oncologists, and neurosurgeons through direct physician ordering, with results returned within 7-10 days and insurance/Medicare billed directly.
  • 3D Predict Platform A proprietary ex vivo 3D cell culture platform that creates up to 1,000 patient-specific microtumors from live cancer cells to predict therapeutic response to cancer treatments before treatment initiation. Underlies Kiyatec's clinical tests and preclinical pharma services.
  • KIYA-Predict A preclinical drug development service platform that enables biopharmaceutical companies to assess therapeutic efficacy of investigational drug candidates using patient-derived 3D spheroid screening, supporting clinical candidate selection and translational oncology programs across solid tumor types.

Quantifiable outcome

  • 85% accurate prediction of clinical response/nonresponse to temozolomide in newly diagnosed HGG patients (P=0.007)
  • +5 more outcomes

Companies that use KIYATEC

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

KIYATEC technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

KIYATEC partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • MBDcoreStrategic or Co-development Partner · 13 November 2025South Korean firm MBD made a strategic investment to accelerate Kiyatec's US commercial expansion. Partnership involves integrating MBD's automation technology into Kiyatec's Greenville, SC laboratory to improve operational efficiency and accelerate launch of diagnostic panels for various cancers.
  • XenoSTARTcoreStrategic or Co-development Partner · 27 June 2023Collaboration to provide correlative ex vivo efficacy data using Kiyatec's 3D spheroid screening platform with XenoSTART's Patient Derived Xenograft (XPDX) models. Partnership helps biopharma rapidly assess efficacy, reduce drug development costs, and expedite the development process.
  • AstraZenecacoreStrategic or Co-development Partner · 23 May 2023Multifaceted research agreement to assess therapeutic efficacy of undisclosed preclinical assets using Kiyatec's KIYA-Predict platform. Agreement aligns with AstraZeneca's strategy of implementing novel oncology solutions with outside partners to develop novel cancer therapeutics.
  • NICO CorporationcoreStrategic or Co-development Partner · 10 October 2022Partnership to improve tissue quality for more accurate tumor response prediction. NICO's automated Myriad tissue resection device and Automated Preservation System (APS) collects and biologically preserves tissue in the operating suite, maintaining tumor microenvironment for better predictive accuracy.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

KIYATEC competitors and assessment

Company assessment

Broad incumbents

  • Natera: Natera is a molecular diagnostics company with a growing oncology franchise (Signatera MRD, etc.). It is a broader oncology diagnostics incumbent, addressing different clinical questions (MRD, monitoring) than KIYATEC but competing for the same oncology budget and physician relationships.
  • Caris Life Sciences: Caris provides molecular profiling (DNA/RNA sequencing and AI-driven biomarker analysis) across oncology and has expanded into therapy selection. It competes for the same oncology diagnostic ordering channel and serves biopharma with companion diagnostic services, overlapping with KIYATEC's clinical and pharma customers.
  • Exact Sciences: Exact Sciences is a major molecular diagnostics company (Cologuard, Oncotype DX, etc.) with an expanding oncology portfolio. It is a broad incumbent in cancer diagnostics that competes for oncologist mindshare, though its platform is largely genomic rather than functional.
  • Foundation Medicine: Foundation Medicine (a Roche subsidiary) is the established leader in comprehensive genomic profiling of solid tumors. It is a broad incumbent in oncology diagnostics, embedded in NCCN guidelines, and competes with KIYATEC for oncologist ordering behavior — though it focuses on genomic rather than functional testing.
  • Tempus Labs: Tempus is a large, multi-modal precision medicine company offering genomic sequencing, AI-driven clinical decision support, and data services across oncology. It is a broader incumbent than KIYATEC — competing for the same oncologist wallet share via molecular profiling — and increasingly adjacent on the functional side through its broader portfolio.

Direct peers

  • Champions Oncology: Champions Oncology offers patient-derived xenograft (PDX) models and translational oncology services for both preclinical drug development and clinical decision support. It is highly comparable to KIYATEC's KIYA-Predict business (preclinical efficacy testing) and overlaps with the clinical side via PDX-guided therapy selection.
  • SEngine Precision Medicine: SEngine Precision Medicine applies patient-derived 3D tumor cultures and high-throughput drug screening to match cancer patients to effective therapies. It directly parallels KIYATEC's 3D Predict methodology (ex vivo 3D cultures + drug panel testing) and serves the same oncologist/patient segment in functional precision oncology.
  • Notable Labs: Notable Labs is a functional precision oncology company that uses patient-derived tumor cells to test drug response ex vivo and predict therapy outcomes. It targets the same clinical use case as KIYATEC's 3D Predict — predicting individual cancer patient response before treatment — making it the closest head-to-head comparable in functional precision medicine.
  • Certis Oncology Solutions: Certis Oncology builds patient-derived 3D tumor models and offers preclinical and translational oncology services for biopharma. It mirrors the KIYA-Predict preclinical service offering (functional/3D efficacy testing for pharma) and competes for the same biopharma customers evaluating investigational oncology assets.

Emerging players

  • Function Oncology: Function Oncology is an earlier-stage company applying functional genomics and precision oncology approaches to identify patient-specific therapeutic vulnerabilities. It overlaps with KIYATEC's functional precision oncology thesis but is at an earlier stage and uses a different (functional genomics) underlying technology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

KIYATEC social profiles

Digital presence

KIYATEC compliance and trust

Trust signal

Compliance2 records

KIYATEC financial estimates

Financial estimate

Revenue estimate

Valuation estimate

KIYATEC leadership team

Management profile

Number of profiles

Profiles10 records

KIYATEC funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

KIYATEC M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KIYATEC

What does KIYATEC do?

KIYATEC operates a proprietary ex vivo 3D cell culture platform that creates up to 1,000 patient-specific microtumors from live cancer cells to predict therapeutic response to chemotherapy before treatment initiation. The company offers the 3D Predict Glioma clinical test (CLIA-certified, CPT 0248U) for newly diagnosed and recurrent high-grade glioma patients screening 12 chemotherapy agents with 7-10 day turnaround, and the KIYA-Predict preclinical service line for biopharmaceutical companies to evaluate investigational oncology drug candidates.

Is KIYATEC a public or private company?

KIYATEC is a private company. It is classified as venture growth investor backed and is currently operating.

When was KIYATEC founded?

KIYATEC was founded in 2008. It employs 11 to 50 people.

Where is KIYATEC based?

KIYATEC is headquartered in Greenville, United States, in the North America region.

How does KIYATEC make money?

Two revenue lines are on record. Clinical Testing Services are the primary driver. The others are drug Development Services (KIYA-Predict).

Who are KIYATEC's main competitors?

Broad incumbents on record are Natera, Caris Life Sciences, Exact Sciences, Foundation Medicine and Tempus Labs. Direct peers are Champions Oncology, SEngine Precision Medicine, Notable Labs and Certis Oncology Solutions. Function Oncology is listed as an emerging player.

Does KIYATEC have an API?

No public API is recorded for KIYATEC.

What industry is KIYATEC in?

KIYATEC's product category is Functional Precision Oncology Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAANAD, Molecular Tumor Boards & Clinical Interpretation Services. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogKiyatec Secures Strategic Investment from South Korean Partner MBD to Accelerate U.S. Commercial ExpansionKiyatec closed a strategic investment round led by South Korean partner MBD to accelerate its U.S. commercial expansion. The partnership will integrate MBD's automated platform into Kiyatec's CLIA/CAP labs in Greenville, SC, to enhance throughput and quality control. The funds will support commercial expansion, AI tool integration, and clinical evidence generation for reimbursement.YahooKiyatec Secures Strategic Investment from South Korean Partner MBD to Accelerate U.S. Commercial ExpansionKiyatec announced a strategic investment from South Korean technology company MBD, aimed at expanding its U.S. testing capabilities and accelerating the launch of cancer diagnostic panels. The partnership involves integrating MBD's automated platform technology into Kiyatec's Greenville laboratory to improve throughput and quality while expanding to multiple cancer types.Business Wire BlogKiyatec and XenoSTART formally announce a collaborative agreement to help reduce drug development costs by providing correlative ex vivo efficacy data using Kiyatec’s 3D spheroid screening platform, KKiyatec and XenoSTART announced a collaboration to use Kiyatec's ex vivo 3D spheroid platform with XenoSTART's XPDX models to reduce drug development costs. The companies will present data at the Tumor Models Summit in Boston on July 12, 2023.FinSMEsKiyatec Receives Investment from Brain Cancer Venture Philanthropy FundsGreenville, South Carolina-based functional precision oncology company Kiyatec received an undisclosed investment from The Brain Tumor Investment Fund and Sontag Innovation Fund. The company plans to use the funds to advance commercialization and adoption of its clinically validated testing platform, 3D-Predict. Kiyatec offers clinical testing for high-grade glioma and is developing assays for ovarian, breast, lung and rare tumors.BraintumorinvestmentfundKiyatec Announces Investment from Leading Brain Cancer Venture Philanthropy FundsKiyatec, Inc. announced a new investment from the venture philanthropy arms of the National Brain Tumor Society and the Sontag Foundation to support the commercialization of its 3D-Predict™ testing platform for glioblastoma. The funding aims to expand access to this clinically validated tool, which helps predict patient response to cancer drugs and guide therapy selection.FinSMEsKiyatec Closes US$18M in Series CGreenville, SC-based precision oncology company Kiyatec has closed an $18 million Series C funding round led by Bruker with participation from Seae Ventures, VentureSouth, and LabCorp. The company intends to use the capital to accelerate the adoption of its commercially available clinical testing and preclinical pharmaceutical services for cancer drug development. This funding supports Kiyatec's efforts to expand its functional precision oncology capabilities across various solid tumor types.PR NewswireUnique Partnership Seeks to Advance Precision Medicine Options for Deadly GBM Brain TumorsNICO Corporation and Kiyatec announced a partnership to improve precision medicine for Glioblastoma Multiforme (GBM) patients by combining NICO's tissue preservation technology with Kiyatec's predictive assay. The collaboration aims to use high-quality, live-cell tissue specimens to accurately predict tumor response to therapies before treatment begins. This initiative seeks to address unmet clinical needs and potentially extend survival times for patients with this aggressive brain cancer.BioSpaceKIYATEC to Present at the KeyBanc Capital Markets’ Life Sciences & MedTech Investor ForumKIYATEC CEO Matt Gevaert will present virtually at KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum on March 23, 2022. The company introduced its first commercial assay, 3D Predict™ Glioma, and is expanding facilities to support five-year growth plans.UPSTATE BUSINESS JOURNALKIYATEC to take over former Chartspan location in downtown GreenvilleKIYATEC will take over the former Chartspan location at 2 N. Main Street in downtown Greenville, becoming the first anchor tenant in the new Innovation District. The company plans to more than triple its Greenville workforce from 20 to 91 jobs and invest over $5 million. Its first commercial product, 3D Predict Glioma, tests for ovarian, breast, rare, and lung cancers.